CAMBRIDGE, Mass. — January 11, 2026 — Leads & Copy — Beam Therapeutics Inc. (Nasdaq: BEAM) announced continued progress toward building a sustainable, predictable model for precision genetic medicines. Recent updates highlight the company’s liver-targeted genetic disease and hematology franchises, along with strategic priorities for 2026, all supported by an extended operating runway.
The company reached alignment with the U.S. Food and Drug Administration (FDA) on a potential accelerated approval pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) based on biomarker endpoints. Beam anticipates submitting a U.S. Biologics Licensing Application (BLA) for risto-cel (previously known as BEAM-101) as early as year-end 2026. They also plan to expand their liver-targeted genetic disease franchise with a new program announcement in the first half of 2026.
Beam Therapeutics ended 2025 with an estimated $1.25 billion in cash, cash equivalents, and marketable securities. The projected operating runway extends into 2029, supporting the anticipated launch of risto-cel and the execution of the BEAM-302 pivotal development plan.
John Evans, chief executive officer of Beam Therapeutics, stated that the company has continued to demonstrate the power and consistency of its base editing platform, working to redefine what is possible in genetic medicine. He emphasized the company’s approach is rooted in precision and predictability, designing one-time treatments to reverse genetic disease and generating differentiated clinical data across programs.
Beam is building a platform approach for single-course, precision gene editing therapies for liver-targeted genetic diseases, delivering base editors through intravenous infusion of lipid-nanoparticles (LNPs). BEAM-302, Beam’s lead genetic disease program, is designed as a liver-targeting therapy for AATD, addressing the underlying pathophysiology of both liver and lung disease. Treatment with BEAM-302 demonstrated the first-ever clinical in vivo genetic correction of a disease-causing mutation and established clinical proof of concept in AATD.
To date, over 25 AATD patients with lung and/or liver disease have been treated in the dose-exploration portions of the trial. To support a future BLA submission, the company anticipates enrolling approximately 50 additional patients to be treated with the selected optimal biologic dose of BEAM-302 in an expansion of the ongoing Phase 1/2 study.
BEAM-302 has been accepted into the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program. Beam expects to report updated data from the Phase 1/2 trial and next steps for pivotal development by the end of the first quarter of 2026.
BEAM-301 aims to correct the most common disease-causing mutation, R83C, in patients with glycogen storage disease type Ia (GSDIa), potentially normalizing blood glucose without continuous supplementation and improving key metabolic parameters. BEAM-301 is currently being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa.
Dosing is complete in the first cohort, and enrollment has been initiated in the second cohort. Beam expects to report initial clinical data in 2026. The next clinical program for its liver-targeted genetic disease franchise is expected to be disclosed in the first half of 2026.
Beam is pursuing a multi-wave development strategy for sickle cell disease (SCD). Risto-cel is an investigational autologous cell therapy for the treatment of SCD. Data from the BEACON Phase 1/2 clinical trial showed evidence of risto-cel’s differentiated treatment profile, demonstrating a deeper resolution of SCD markers and reduced time in the hospital. The adult and adolescent cohorts of the BEACON trial were fully enrolled in mid-2025, and manufacturing of all doses was completed as of December 2025.
Beam completed interactions with the FDA on the anticipated BLA package for risto-cel, which is expected to align with regulatory precedent. Risto-cel has also been accepted into the FDA’s CDRP program. Beam expects to submit a BLA for risto-cel as early as year-end 2026.
Beam is also prioritizing in vivo delivery for its next wave approach in SCD, complementing risto-cel. The ongoing Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody (mAb) that enables ESCAPE, is expected to complete dosing in the first half of 2026. Multiple targeted LNPs for HSC delivery have been identified and are in lead optimization.
Beam Therapeutics estimates it had $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025, inclusive of the $255.1 million in closing cash consideration received from the acquisition of Orbital Therapeutics by Bristol-Myers Squibb. Beam expects that its estimated cash, cash equivalents and marketable securities will enable the company to cover its anticipated operating expenses and capital expenditure requirements into 2029.
Management will present and discuss Beam’s pipeline and business updates at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT. A live webcast will be available in the investor section of the company’s website.
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Josie Butler
1AB
josie@1abmedia.com
Source: Beam Therapeutics
